logo
Download Download 182
Views 796

Details

Cost-effectiveness and availability of alternative treatment options play a crucial role in the listing of new medicines in South Korea. However, high-cost medicines with no alternative treatment options, particularly those for treating cancer and rare diseases, were not reimbursed under the traditional route.

How the government of South Korea addresses this issue? Learn more from this policy brief.

Related Projects